Celsentri® (maraviroc) tablets for CCR5‑tropic HIV‑1

What Celsentri® Is and How It Works

Celsentri® contains maraviroc, a CCR5 antagonist used with other antiretrovirals to treat CCR5‑tropic HIV‑1. It is taken by mouth as tablets, usually twice daily. Dosing depends on other medicines that raise or lower maraviroc levels. A tropism test is needed because it does not work for CXCR4‑tropic or dual/mixed virus. If you are comparing Celsentri cost without insurance, many patients find Canadian pricing helps them stay on therapy.

YouDrugstore is a licensed Canadian pharmacy based in Manitoba. We meet Canadian pharmacy standards, and our pharmacists review prescriptions before dispensing. We carry brand and generic medicines at Canadian prices, plus OTC health products, and we ship to the US.

We partner with licensed international pharmacies that we vet for quality, so you receive authentic brand medicines and a broad selection at fair prices.

Dosage and Usage

Celsentri® dosing varies with drug interactions. Maraviroc is a CYP3A substrate. Strong inhibitors lower clearance, and strong inducers raise it. Follow your prescriber’s plan and the product label.

• Typical adult dose without strong inhibitors/inducers: 300 mg twice daily.
• With strong CYP3A inhibitors (for example, some protease inhibitors or azole antifungals): 150 mg twice daily.
• With strong CYP3A inducers without inhibitors (for example, rifampin or certain anticonvulsants): 600 mg twice daily.
• Take with or without food. Swallow tablets whole with water.
• If you miss a dose, take it when remembered unless it is close to the next dose. Do not double doses.
• Tell your care team about liver or kidney problems. Dosing may change in severe impairment, especially with interacting drugs.

• Storage: store at room temperature, 15–30°C (59–86°F), dry and away from light.
• Travel: keep tablets in the original labeled bottle in your carry‑on. Pack enough for your trip plus extra. Set reminders to keep doses on schedule across time zones.

Benefits and Savings

With an active background regimen, maraviroc helps lower viral load and supports CD4 cell recovery. It targets CCR5, a co‑receptor used by many HIV‑1 strains. The tablet can be taken with or without food, which supports daily routines.

Ordering through YouDrugstore may lower your monthly spend. Many customers report 60–80% savings versus typical US pharmacy prices. This can be helpful for those managing HIV care without insurance. Reorder reminders can help you avoid gaps.

Side Effects and Safety

Most people tolerate maraviroc well, but side effects can occur. Seek urgent care for signs of a severe reaction.

• Common: cough, upper respiratory symptoms, fever, rash, headache, dizziness, sleep disturbance, nausea, diarrhea, stomach discomfort, muscle or joint pain.
• Less common: elevated liver enzymes, low blood pressure with dizziness or fainting, infections including pneumonia, anemia.
• Serious: liver problems (yellowing skin or eyes, dark urine, severe stomach pain), severe rash or hypersensitivity, chest pain or fainting, severe infections. Stop the drug and get care if severe symptoms appear.

Maraviroc may cause postural hypotension, especially in patients with cardiovascular disease or renal impairment. Hepatotoxicity has been reported, sometimes with allergic features. Use caution in severe kidney impairment, particularly when combined with potent CYP3A inhibitors. Do not use for CXCR4‑tropic or dual/mixed‑tropic HIV‑1. Review all medicines and supplements for interactions, including rifampin, certain anticonvulsants, macrolides, azoles, protease inhibitors, and St. John’s wort. Ask about pregnancy and breastfeeding considerations.

Onset Time

Viral load often begins to decline within 2–4 weeks when maraviroc is paired with an effective background regimen. CD4 counts may rise over subsequent weeks. The full response depends on baseline resistance, adherence, and the other antiretrovirals in the regimen.

Compare With Alternatives

Celsentri® is used with other HIV medicines rather than alone. Many patients use an integrase inhibitor‑based regimen for initial therapy. Single‑tablet options such as Biktarvy® combine three agents once daily and are widely used in treatment‑naive populations. Celsentri® is more often used in treatment‑experienced patients with confirmed CCR5‑tropic virus.

When resistance or intolerance limits choices, an NNRTI like Intelence® (etravirine) may be part of the backbone. A nucleoside backbone such as emtricitabine/tenofovir is common, and selection should consider renal and bone health, HBV status, and interactions. Your care team will tailor therapy using resistance testing and tropism results.

Combination Therapy

Maraviroc must be combined with other active antiretrovirals. It blocks CCR5 on host cells and does not suppress replication alone. Regimens often include two nucleos(t)ide reverse transcriptase inhibitors plus a third agent, or a boosted protease inhibitor‑based approach. Tropism testing guides use. If the virus uses CXCR4, maraviroc will not be effective.

Coinfection with hepatitis B or C influences regimen design. Agents with HBV activity are important in chronic HBV. Liver monitoring is prudent when starting, stopping, or switching components.

Patient Suitability and Cost-Saving Tips

Celsentri® may suit adults with confirmed CCR5‑tropic HIV‑1 who need an additional active agent. It is not appropriate for CXCR4 or dual/mixed tropism. Caution is advised with significant liver disease, severe renal impairment with potent CYP3A inhibitors, or a history of fainting. Dose selection hinges on interaction screening.

To manage costs, ask about available strengths and whether a generic maraviroc option is suitable for you. Multi‑month supplies can lower the per‑month price, and we offer reorder reminders to support adherence. For current promotions and bulk options, see our Celsentri coupon page. Savings can help when purchasing therapy without insurance.

You can browse related topics such as Hiv 1 Infection to view other treatments. If hepatitis B is part of your health plan, visit Chronic Hepatitis B Virus Infection to review HBV‑active options.

Authoritative Sources

Review the manufacturer’s information on the ViiV Healthcare Celsentri page. You can also check the Health Canada Drug Product Database entry and the FDA Prescribing Information for detailed safety and interaction data.

YouDrugstore makes it simple to order from a licensed Canadian pharmacy, with pharmacist review before dispensing and friendly customer‑service chat during posted hours. We offer prompt, express shipping to the US, with careful packaging for your medicines.

This content is for general information only and does not replace your prescriber’s advice. Always follow the directions on your prescription label and the guidance from your healthcare team.